Metastatic Castration-Resistant Prostate Cancer

Fillmore and his collaborators have investigated optimization strategies for the management of metastatic castration-resistant prostate cancer, with a focus on comparative effectiveness and precision medicine. His research demonstrates that docetaxel rechallenge may offer superior overall survival compared to cabazitaxel in select patients and that enzalutamide may provide survival advantages over abiraterone acetate. Additionally, he has utilized molecular clustering to identify distinct somatic mutations and signatures, providing a framework for patient stratification and targeted therapeutic interventions.